187 related articles for article (PubMed ID: 34427833)
21. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
22. High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer.
Li C; Cui Y; Liu LF; Ren WB; Li QQ; Zhou X; Li YL; Li Y; Bai XY; Zu XB
Clin Genitourin Cancer; 2017 Oct; 15(5):570-576. PubMed ID: 28648755
[TBL] [Abstract][Full Text] [Related]
23. Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma.
Gao KT; Lian D
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3561-5. PubMed ID: 27649655
[TBL] [Abstract][Full Text] [Related]
24. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
Ye ZY; Cao YB; Lin TY; Lin HL
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
[TBL] [Abstract][Full Text] [Related]
25. TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK; Ch'ng ES; Md Salleh MS; Banham AH; Pedersen LM; Møller MB; Green TM; Wong KK
Histopathology; 2017 Jul; 71(1):98-111. PubMed ID: 28248435
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma.
Zhang HM; Yang FQ; Chen SJ; Che J; Zheng JH
Tumour Biol; 2015 Apr; 36(4):2947-55. PubMed ID: 25480417
[TBL] [Abstract][Full Text] [Related]
27. MLL2 protein is a prognostic marker for gastrointestinal diffuse large B-cell lymphoma.
Ye H; Lu L; Ge B; Gao S; Ma Y; Liang B; Yu K; Yang K
Int J Clin Exp Pathol; 2015; 8(10):13043-50. PubMed ID: 26722499
[TBL] [Abstract][Full Text] [Related]
28. Prognosis and complications of patients with primary gastrointestinal diffuse large B-cell lymphoma: Development and validation of the systemic inflammation response index-covered score.
Chu Y; Liu Y; Jiang Y; Ge X; Yuan D; Ding M; Qu H; Liu F; Zhou X; Wang X
Cancer Med; 2023 Apr; 12(8):9570-9582. PubMed ID: 36866830
[TBL] [Abstract][Full Text] [Related]
29. [Effect of Lymphocyte/Monocyte Ratio on Clinical Features and Prognosis of Patients with Primary Gastrointestinal Diffuse Large B Cell Lymphoma].
Xu YX; Zhang YG; Xu CL; Liu NJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1404-1409. PubMed ID: 27784365
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
31. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
32. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
34. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer.
Zheng HT; Shi DB; Wang YW; Li XX; Xu Y; Tripathi P; Gu WL; Cai GX; Cai SJ
Int J Clin Exp Pathol; 2014; 7(6):3174-81. PubMed ID: 25031737
[TBL] [Abstract][Full Text] [Related]
35. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
36. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
37. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
38. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
39. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma.
Gao R; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Yang T; Xu W
Int J Cancer; 2018 Oct; 143(8):1884-1895. PubMed ID: 29744861
[TBL] [Abstract][Full Text] [Related]
40. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
